Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07604116
PHASE1

A Study to Evaluate Satety, Tolerability, Biodistribution, Radiation Dosimetry, and Pharmacokinetics of SST001 in Healthy Volunteers, Patients With PD and Patients With MSA

Sponsor: Synusight Biotech (Shanghai) Co., Ltd.

View on ClinicalTrials.gov

Summary

The non-randomized, open-label phase I study aims to evaluate the safety, tolerability, biodistribution, radiation dosimetry, and pharmacokinetics of SST001 in healthy volunteers, patients with MSA and patients with PD.

Official title: A Non-Randomized, Open-Label Phase I Study to Evaluate the Safety, Tolerability, Biodistribution, Radiation Dosimetry, and Pharmacokinetics of SST001 in Healthy Volunteers, Patients With Multiple System Atrophy, and Patients With Parkinson's Disease

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2026-06-15

Completion Date

2027-02

Last Updated

2026-09-01

Healthy Volunteers

Yes

Interventions

DRUG

SST001

Participants will undergo PET imaging after administration.

Locations (2)

Affiliated Hospital of Jiangnan University

Wuxi, Jiangsu, China

Huashan Hospital, Fudan University

Shanghai, Shanghai Municipality, China